Join us at the 2022 ASCO Annual Meeting
to discover NavDx® – the first and only clinically validated circulating
tumor-tissue–modified viral (TTMV®)-HPV DNA blood test.

Stop by booth #21152 to learn about the technology that
is transforming the management of HPV-driven cancers.

We invite you to attend the Oral Abstract Session
Head and Neck Cancer Track (S406)
Association of plasma tumor-tissue­­–modified viral (TTMV)-HPV DNA
with tumor burden, treatment type, and outcome:
A translational analysis from NRG-HN002 (#6006)
Friday, June 3, 4:45pm CDT
McCormick Place Convention Center
For conference registrants,
click to live-stream

We look forward to your visit!
Unable to attend?
Go to www.virtual.naveris.com
for your own NavDx experience.

Naveris Inc., 22 Strathmore Road, Natick, MA 01760-2434
www.naveris.com | contact@naveris.com
© 2022 Naveris Inc. US Patent 11,168,373 NavDx-0522-136